Peptide receptor radionuclide therapy alone or in combination with temozolomide plus/minus capecitabine in [<sup>18</sup>F]FDG-positive metastatic neuroendocrine tumors.

In the pre-specified final analysis of OS of the phase 3 NETTER-1 trial [ 12 ], with a median follow-up of over 6.3 years, the intention-to-treat population did not reach statistical significance (HR 0.84; 95% CI: 0.60–1.17; p = 0.30), likely influenced by a high crossover rate (36%).

also in 111,027 other papers